What’s Happening With Cannabis Stocks in May 2023?

Cannabis stocks were up this week, as the market began to turn, but how long will it last, and is more growth coming?

| More on:
Cannabis grows at a commercial farm.

Source: Getty Images

It’s starting to look like perhaps cannabis stocks may have hit rock bottom this week. After shares across the board fell lower and lower in 2023, there is a slight uptick recently. But it’s not necessarily due to cannabis stocks themselves.

Market positivity

It seems as though Canadian investors may finally be interested in looking for growth stocks again. Companies continued to hit 52-week lows again and again over the last few months, especially among cannabis stocks. As earnings continue to roll in across the board, however, some investors are jumping on the opportunity to buy low.

This may include those companies in the cannabis market. After hitting 52-week lows, Canopy Growth (TSX:WEED), Tilray (TSX:TLRY), Aurora Cannabis (TSX:ACB) and others all saw an increase in share price. Canopy Growth stock is up 5%, Tilray stock is up 27%, and Aurora stock is up 12% since hitting 52-week lows.

What about the cannabis industry?

News in the cannabis market hasn’t had anything too crazy to allow for a larger increase. However, this could change in the near future. More and more states in the United States continue to climb aboard the cannabis train, with the multi-billion-dollar industry promising more tax incentives and job growth.

In April, Delaware became the 22nd state to legalize recreational marijuana. However, it looks like Ohio, Pennsylvania and Florida may be next on board. This could occur as soon as the end of the year, if perhaps not next year during the next election.

Florida has already been making headlines, as the state recently passed legislation this month to allow medicinal cannabis patients to renew prescriptions through telehealth appointments. While it still needs to run up to the governor, it’s looking promising in such a conservative state.

More movement could come from the Senate soon, as the Secure and Fair Enforcement (SAFE) Banking Act could be passed. This would protect banks that work with cannabis businesses in states where it is legal.

Still a waiting game

Right now, cannabis stocks remain in a waiting game. Each of these companies will continue to have to prove themselves and their path to profits. While Tilray stock remains the only profitable one of the bunch, others may soon climb towards it. But most are awaiting legalization in the United States for that to be a sure thing.

This is why so many cannabis stocks have expanded to other sources of revenue. Tilray stock, for one, now has partnerships for beer production. Canopy Growth stock touts its BioSteel as a huge win. Aurora stock, meanwhile, has remained focused on the marijuana industry, and looks to expand in the medical marijuana sector. However, it’s also had to sell much of its locations and medical marijuana acquisitions to bring in funds.

Bottom line

These cannabis stocks may be on the upswing for now, but it’s still a very volatile market. If you’re interested in cannabis stocks over the long haul, then great! These three cannabis stocks may be a great option.

However, if you’re hoping for a quick turnaround and growth that we saw back in 2018 and 2017, I would hold out longer. We still need a lot of legalization to occur not just around the world but specifically in the United States. This would make the country the largest producer and consumer of marijuana in the world, creating a huge opportunity for investors.

Until then, however, perhaps it’s better to wait on the sidelines.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Amy Legate-Wolfe has positions in Canopy Growth. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

More on Cannabis Stocks

edit Jars of marijuana
Cannabis Stocks

Is Tilray Stock a Buy in the New Bullish Market?

Canadian cannabis producer Tilray has underperformed the broader markets in the last five years due to its weak fundamentals.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 10-Foot Pole

Down 99% from all-time highs, Aurora Cannabis stock remains a high-risk bet due to its weak fundamentals and risky liquidity…

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Has Been on a Roller Coaster: Is it a Good Buy?

In their relatively small lifetime, most cannabis stocks in Canada have seen both extreme highs and massive slumps. But their…

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Canopy Growth Stock Surged 100% Last Month: Is It a Good Buy Now?

Canopy Growth soared more than 160% last month. Can the TSX cannabis stock continue to mover higher in 2024?

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth Stock Is Rising But I’m Worried About This One Thing

Canopy Growth stock is soaring as the legalization effort makes real progress in both Germany and the United States.

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »